Cygnos Biotech Llc
CYGNOS BioTech is developing propriety antimicrobial therapeutics protected under several patents. PVX that will be commercialized for human and veterinary clinical markets. PVX is currently manufactured by chemical modification of the protein to ultimately promote biologic activity, either antiviral or antitumor (MMX). CYGNOS PVX has already demonstrated efficacy in companion animals (dogs, cats, horses and birds). CYGNOS has been awarded 2 FDA investigational product INADs for PVX and MMX. In parallel, CYGNOS is seeking funding to advance product development through FDA for the approval of the Animal INADs and a Human IND submission.
7-day free trial · no credit card
Verified contacts
2
available on Kipplo
LinkedIn employees
2
1 to 10 range
Open roles
—
no listings
Distinct roles
2
indexed titles
Tech stack
0
tools in use
Monthly traffic
—
organic / mo
Sign up free to see all 2 verified contacts at Cygnos Biotech Llc
Free for 7 days · 50 credits · no card · only pay for verified records.
Decision-makers and verified team members
2 contacts with verified email or phone · masked until revealed.
- DS
Debbie Somers
Health IT and Disability Policy Consultant · Other
EmailPhone - WC
Walid Chaar
Chief Technology Officer · Information Technology
EmailPhone
Showing 2 of 2 verified contacts
Top roles at Cygnos Biotech Llc
2 distinct titles indexed · top 2 shown.
- 1chief technology officer
- 1health it and disability policy consultant
Sign up to unlock all 2 contacts at Cygnos Biotech Llc
Free for 7 days · 50 credits · no card · only pay for verified records.
Sign up to reveal 2 verified contacts at Cygnos Biotech Llc
7-day trial · no credit card · cancel anytime · only pay for verified records.
Trusted by sales, marketing, and GTM engineering teams.